A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI)

At a glance

Drugs Ridinilazole (Primary) ; Vancomycin
Indications Clostridium difficile infections
Focus Therapeutic Use
Acronyms Ri-CoDIFy 2
Sponsors Summit Therapeutics

Most Recent Events

11 Dec 2018 According to a Summit Therapeutics media release, design of this trial presented at IDWeek conference.
11 Jul 2018 Status changed from planning to not yet recruiting.
27 Mar 2018 According to a Summit Therapeutics media release, this trial is planned to initiate in the Q1 2019.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight

A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI)

A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI)

At a glance

Most Recent Events

Table of Contents

About Our Content

Other Sites

Help & Contacts

Downloads

Legal